FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1856906265> ?p ?o ?g. }

• W1856906265 endingPage "244" @default.
• W1856906265 startingPage "239" @default.
• W1856906265 abstract "The aim of this study was to evaluate the efficacy and safety of a newly manufactured botulinum toxin, Neuronox, compared with BOTOX for the treatment of the spastic equinus gait in children with cerebral palsy.A total of 127 children with cerebral palsy, aged 2 to 10 years, who presented at three university hospitals with spastic equinus gait were assessed for eligibility to participate in this double-blinded, randomized, controlled trial. Of the 119 eligible participants (mean age 4.33 y; SD 2.07; 76 males and 43 females; 79 with diplegia and 40 with hemiplegia), 57 were classified as Gross Motor Function Classification System level I, 29 as level II, and 33 as level III. Participants were randomly assigned to receive an injection of Neuronox (n=60) or BOTOX (n=59) to the calf muscles at a dose of 4U/kg for those with hemiplegia and 6U/kg for those with diplegia. Assessments were performed at baseline (V1) and at 4 (V2), 12 (V3), and 24 (V4) weeks after the intervention. The primary outcome measure was response rate at V3, with a positive response being defined as at least a 2-point increase in the Physicians' Rating Scale (PRS) score. The non-inferiority margin was set as -20% for the difference in the response rate. The secondary outcome measures included PRS score, passive range of motion (PROM) of the ankle and knee, and Gross Motor Function Measure 88 (GMFM-88). Any adverse events were investigated for safety implications.The response rate of the Neuronox group at V3 was not inferior to that of the BOTOX group (90% lower limit=-11.58%). There were significant improvements in PRS, PROM of ankle dorsiflexion, and GMFM scores at V2, V3, and V4 in both groups. The changes in PRS score were not statistically different between the two groups in serial evaluation (p=0.96). PROM of the ankle dorsiflexion increased without any significant difference between the two groups, either overall (p=0.56) or at each visit (V2, p=0.32; V3, p=0.66; V4, p=0.90). The increase in GMFM score in serial measurements were not significantly different between the two groups (p=0.16), whereas it was larger in the BOTOX group than in the Neuronox group at V2 and V4 (p=0.03 and 0.05 respectively). The frequency of adverse events was not significantly different between the two groups (p=0.97), and drug-related complications of Neuronox treatment were not addressed.The outcomes of Neuronox, based on PRS, proved to be as effective and safe as those of BOTOX for the treatment of spasticity in individuals with cerebral palsy." @default.
• W1856906265 created "2016-06-24" @default.
• W1856906265 creator A5003400880 @default.
• W1856906265 creator A5004569036 @default.
• W1856906265 creator A5007810268 @default.
• W1856906265 creator A5027659503 @default.
• W1856906265 creator A5053224934 @default.
• W1856906265 creator A5055848399 @default.
• W1856906265 date "2010-11-18" @default.
• W1856906265 modified "2023-10-05" @default.
• W1856906265 title "Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial" @default.
• W1856906265 cites W1965168638 @default.
• W1856906265 cites W1966707243 @default.
• W1856906265 cites W1989576765 @default.
• W1856906265 cites W2005607749 @default.
• W1856906265 cites W2008285675 @default.
• W1856906265 cites W2009830772 @default.
• W1856906265 cites W2028067695 @default.
• W1856906265 cites W2041335060 @default.
• W1856906265 cites W2050083593 @default.
• W1856906265 cites W2057119583 @default.
• W1856906265 cites W2062832833 @default.
• W1856906265 cites W2093345614 @default.
• W1856906265 cites W2094841320 @default.
• W1856906265 cites W2095447090 @default.
• W1856906265 cites W2102725093 @default.
• W1856906265 cites W2106947530 @default.
• W1856906265 cites W2108696783 @default.
• W1856906265 cites W2119749887 @default.
• W1856906265 cites W2135518675 @default.
• W1856906265 cites W2137847719 @default.
• W1856906265 cites W2144383590 @default.
• W1856906265 cites W2158968342 @default.
• W1856906265 cites W4248221578 @default.
• W1856906265 cites W69472607 @default.
• W1856906265 doi "https://doi.org/10.1111/j.1469-8749.2010.03830.x" @default.
• W1856906265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21087238" @default.
• W1856906265 hasPublicationYear "2010" @default.
• W1856906265 type Work @default.
• W1856906265 sameAs 1856906265 @default.
• W1856906265 citedByCount "30" @default.
• W1856906265 countsByYear W18569062652012 @default.
• W1856906265 countsByYear W18569062652013 @default.
• W1856906265 countsByYear W18569062652014 @default.
• W1856906265 countsByYear W18569062652015 @default.
• W1856906265 countsByYear W18569062652016 @default.
• W1856906265 countsByYear W18569062652017 @default.
• W1856906265 countsByYear W18569062652018 @default.
• W1856906265 countsByYear W18569062652019 @default.
• W1856906265 countsByYear W18569062652020 @default.
• W1856906265 countsByYear W18569062652021 @default.
• W1856906265 countsByYear W18569062652022 @default.
• W1856906265 countsByYear W18569062652023 @default.
• W1856906265 crossrefType "journal-article" @default.
• W1856906265 hasAuthorship W1856906265A5003400880 @default.
• W1856906265 hasAuthorship W1856906265A5004569036 @default.
• W1856906265 hasAuthorship W1856906265A5007810268 @default.
• W1856906265 hasAuthorship W1856906265A5027659503 @default.
• W1856906265 hasAuthorship W1856906265A5053224934 @default.
• W1856906265 hasAuthorship W1856906265A5055848399 @default.
• W1856906265 hasBestOaLocation W18569062651 @default.
• W1856906265 hasConcept C131872663 @default.
• W1856906265 hasConcept C141071460 @default.
• W1856906265 hasConcept C151800584 @default.
• W1856906265 hasConcept C168563851 @default.
• W1856906265 hasConcept C1862650 @default.
• W1856906265 hasConcept C2776195251 @default.
• W1856906265 hasConcept C2776659555 @default.
• W1856906265 hasConcept C2777364248 @default.
• W1856906265 hasConcept C2778640784 @default.
• W1856906265 hasConcept C2779421357 @default.
• W1856906265 hasConcept C2779593963 @default.
• W1856906265 hasConcept C2779636300 @default.
• W1856906265 hasConcept C71924100 @default.
• W1856906265 hasConcept C99508421 @default.
• W1856906265 hasConceptScore W1856906265C131872663 @default.
• W1856906265 hasConceptScore W1856906265C141071460 @default.
• W1856906265 hasConceptScore W1856906265C151800584 @default.
• W1856906265 hasConceptScore W1856906265C168563851 @default.
• W1856906265 hasConceptScore W1856906265C1862650 @default.
• W1856906265 hasConceptScore W1856906265C2776195251 @default.
• W1856906265 hasConceptScore W1856906265C2776659555 @default.
• W1856906265 hasConceptScore W1856906265C2777364248 @default.
• W1856906265 hasConceptScore W1856906265C2778640784 @default.
• W1856906265 hasConceptScore W1856906265C2779421357 @default.
• W1856906265 hasConceptScore W1856906265C2779593963 @default.
• W1856906265 hasConceptScore W1856906265C2779636300 @default.
• W1856906265 hasConceptScore W1856906265C71924100 @default.
• W1856906265 hasConceptScore W1856906265C99508421 @default.
• W1856906265 hasIssue "3" @default.
• W1856906265 hasLocation W18569062651 @default.
• W1856906265 hasLocation W18569062652 @default.
• W1856906265 hasOpenAccess W1856906265 @default.
• W1856906265 hasPrimaryLocation W18569062651 @default.
• W1856906265 hasRelatedWork W1856906265 @default.
• W1856906265 hasRelatedWork W1953677238 @default.
• W1856906265 hasRelatedWork W1969856249 @default.
• W1856906265 hasRelatedWork W2035344508 @default.

• next